Compare KFFB & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KFFB | CCEL |
|---|---|---|
| Founded | 2005 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Managed Health Care |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 35.8M |
| IPO Year | 2005 | 1997 |
| Metric | KFFB | CCEL |
|---|---|---|
| Price | $4.31 | $3.57 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.9K | ★ 3.9K |
| Earning Date | 11-06-2025 | 10-15-2025 |
| Dividend Yield | N/A | ★ 10.26% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | $9,467,000.00 | ★ $31,747,500.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.85 | ★ N/A |
| Revenue Growth | ★ 26.65 | N/A |
| 52 Week Low | $1.96 | $3.57 |
| 52 Week High | $4.97 | $8.86 |
| Indicator | KFFB | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.95 | 42.18 |
| Support Level | $4.19 | $4.04 |
| Resistance Level | $4.44 | $4.08 |
| Average True Range (ATR) | 0.23 | 0.18 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 24.14 | 31.96 |
Kentucky First Federal Bancorp is a holding company. The company, through its subsidiaries, is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans, and types of deposits etc. The company mainly operates in Perry, Franklin, Boyle, and Garrard and surrounding counties in Kentucky, USA.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.